Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin

International Journal of Oncology

Volumn 49, Issue 3, 2016, Pages 1185-1194

  Altai, Mohamed ^a   Liu, Hao ^b   Orlova, Anna ^a   Tolmachev, Vladimir ^a   Gräslund, Torbjörn ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

111In; Affibody molecule; Albumin binding domain; Biodistribution; HER2; Immunotoxin; PE38

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 AFFIBODY ALBUMIN BINDING DOMAIN PE38X8 TOXIN CONJUGATE; HER2 AFFIBODY PE38 TOXIN CONJUGATE; HER2 AFFIBODY PE38X8 TOXIN CONJUGATE; IMMUNOTOXIN; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; HER2 AFFITOXIN; HYBRID PROTEIN; IMMUNOLOGIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG SELECTIVITY; DRUG TARGETING; DRUG UPTAKE; FEMALE; IN VITRO STUDY; INTERNALIZATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANIMAL; CHEMISTRY; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTOXINS; MICE; NEOPLASMS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION;

EID: 84978531659     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3614     Document Type: Article

References (54)

1. Pohlmann PR, Mayer IA and Mernaugh R: Resistance to trastuzumab in breast cancer. Clin Cancer Res 15: 7479-7491, 2009.
2. Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 13: 714-726, 2013.
3. Rosenzweig SA: Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol 83: 1041-1048, 2012.
4. Kim EG and Kim KM: Strategies and advancement in antibodydrug conjugate optimization for targeted cancer therapeutics. Biomol Ther (Seoul) 23: 493-509, 2015.
5. Kreitman RJ: Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 23: 1-13, 2009.
6. Alewine C, Hassan R and Pastan I: Advances in anticancer immunotoxin therapy. Oncologist 20: 176-185, 2015.
7. Martin-Killias P, Stefan N, Rothschild S, Plückthun A and Zangemeister-Wittke U: A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin Cancer Res 17: 100-110, 2011.
8. Zielinski R, Lyakhov I, Jacobs A, Chertov O, Kramer-Marek G, Francella N, Stephen A, Fisher R, Blumenthal R and Capala J: Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother 32: 817-825, 2009.
9. Zielinski R, Lyakhov I, Hassan M, Kuban M, Shafer-Weaver K, Gandjbakhche A and Capala J: HER2-affitoxin: A potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin Cancer Res 17: 5071-5081, 2011.
10. Liu H, Seijsing J, Frejd FY, Tolmachev V and Gräslund T: Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain. Int J Oncol 47: 601-609, 2015.
11. Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, Venzon DJ, Tsang KY, Benhar I and Pastan I: Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc Natl Acad Sci USA 109: E3597-E3603, 2012.
12. Onda M, Beers R, Xiang L, Nagata S, Wang Q-C and Pastan I: An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 105: 11311-11316, 2008.
13. Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L and Pastan I: Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci USA 109: 11782-11787, 2012.
14. Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ and Pastan I: Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci USA 108: 5742-5747, 2011.
15. King C, Garza EN, Mazor R, Linehan JL, Pastan I, Pepper M and Baker D: Removing T-cell epitopes with computational protein design. Proc Natl Acad Sci USA 111: 8577-8582, 2014.
16. Vuhai-Luuthi MT, Jolivet A, Jallal B, Salesse R, Bidart JM, Houllier A, Guiochon-Mantel A, Garnier J and Milgrom E: Monoclonal antibodies against luteinizing hormone receptor. Immunochemical characterization of the receptor. Endocrinology 127: 2090-2098, 1990.
17. Reiter Y, Brinkmann U, Jung SH, Lee B, Kasprzyk PG, King CR and Pastan I: Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem 269: 18327-18331, 1994.
18. Bera TK, Viner J, Brinkmann E and Pastan I: Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res 59: 4018-4022, 1999.
19. Schmidt M, McWatters A, White RA, Groner B, Wels W, Fan Z and Bast RC Jr: Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol Oncol 80: 145-155, 2001.
20. Wang L, Liu B, Schmidt M, Lu Y, Wels W and Fan Z: Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. Prostate 47: 21-28, 2001.
21. Shinohara H, Morita S, Kawai M, Miyamoto A, Sonoda T, Pastan I and Tanigawa N: Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. J Surg Res 102: 169-177, 2002.
22. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ and Pastan I: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapyresistant hairy-cell leukemia. N Engl J Med 345: 241-247, 2001.
23. Thurber GM, Schmidt MM and Wittrup KD: Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60: 1421-1434, 2008.
24. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S and Frejd FY: Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584: 2670-2680, 2010.
25. Orlova A, Magnusson M, Eriksson TLJ, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, et al: Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66: 4339-4348, 2006.
26. Tolmachev V, Rosik D, Wållberg H, Sjöberg A, Sandström M, Hansson M, Wennborg A and Orlova A: Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 37: 613-622, 2010.
27. Tolmachev V, Malmberg J, Hofström C, Abrahmsén L, Bergman T, Sjöberg A, Sandström M, Gräslund T and Orlova A: Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTAZIGF1R: 4551. J Nucl Med 53: 90-97, 2012.
28. Tolmachev V, Varasteh Z, Honarvar H, Hosseinimehr SJ, Eriksson O, Jonasson P, Frejd FY, Abrahmsen L and Orlova A: Imaging of platelet-derived growth factor receptor expression in glioblastoma xenografts using affibody molecule 111In-DOTAZ09591. J Nucl Med 55: 294-300, 2014.
29. Orlova A, Malm M, Rosestedt M, Varasteh Z, Andersson K, Selvaraju RK, Altai M, Honarvar H, Strand J, Ståhl S, et al: Imaging of HER3-expressing xenografts in mice using a (99m) Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule. Eur J Nucl Med Mol Imaging 41: 1450-1459, 2014.
30. Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P and Capala J: 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging 38: 1967-1976, 2011.
31. Orlova A, Wållberg H, Stone-Elander S and Tolmachev V: On the selection of a tracer for PET imaging of HER2-expressing tumors: Direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 50: 417-425, 2009.
32. Heskamp S, Laverman P, Rosik D, Boschetti F, van der Graaf WT, Oyen WJ, van Laarhoven HW, Tolmachev V and Boerman OC: Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med 53: 146-153, 2012.
33. Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G, Gandjbakhche A and Capala J: Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res 14: 3840-3849, 2008.
34. Lundberg E, Höidén-Guthenberg I, Larsson B, Uhlén M and Gräslund T: Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods 319: 53-63, 2007.
35. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandström M, Rosik D, Carlsson J, Lundqvist H, et al: Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 67: 2773-2782, 2007.
36. Orlova A, Jonsson A, Rosik D, Lundqvist H, Lindborg M, Abrahmsen L, Ekblad C, Frejd FY and Tolmachev V: Sitespecific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albuminbinding domain fusion protein. J Nucl Med 54: 961-968, 2013.
37. Altai M, W ållberg H, H onarvar H, S trand J, O rlova A, Varasteh Z, Sandström M, Löfblom J, Larsson E, Strand SE, et al: 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. J Nucl Med 55: 1842-1848, 2014.
38. Sörensen J, Sandberg D, Sandström M, Wennborg A, Feldwisch J, Tolmachev V, Åström G, Lubberink M, Garske-Román U, Carlsson J, et al: First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med 55: 730-735, 2014.
39. Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandström M, Lubberink M, Olofsson H, et al: Measuring HER2-receptor expression in metastatic breast cancer using [(68)Ga]ABY-025 Affibody PET/CT. Theranostics 6: 262-271, 2016.
40. Makrides SC, Nygren PA, Andrews B, Ford PJ, Evans KS, Hayman EG, Adari H, Uhlén M and Toth CA: Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J Pharmacol Exp Ther 277: 534-542, 1996.
41. Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsén L and Ekblad C: Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 286: 5234-5241, 2011.
42. Jonsson A, Dogan J, Herne N, Abrahmsén L and Nygren P-A: Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel 21: 515-527, 2008.
43. Tolmachev V, Hofström C, Malmberg J, Ahlgren S, Hosseinimehr SJ, Sandström M, Abrahmsén L, Orlova A and Gräslund T: HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [99(m)Tc(CO)3](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. Bioconjug Chem 21: 2013-2022, 2010.
44. Orlova A, Rosik D, Sandström M, Lundqvist H, Einarsson L and Tolmachev V: Evaluation of [(111/114m)In]CHX-A''-DTPAZHER2: 342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors. Q J Nucl Med Mol Imaging 51: 314-323, 2007.
45. Wållberg H and Orlova A: Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 23: 435-442, 2008.
46. Varasteh Z and Orlova A: Comparing the measured affinity of 111In-labeled ligands for cellular receptors by monitoring gamma, beta, or x-ray radiation with three different LigandTracer devices. J Radioanal Nucl Chem 304: 823-828, 2015.
47. Altai M, Strand J, Rosik D, Selvaraju RK, Eriksson Karlström A, Orlova A and Tolmachev V: Influence of nuclides and chelators on imaging using affibody molecules: Comparative evaluation of recombinant affibody molecules site-specifically labeled with 68Ga and 111In via maleimido derivatives of DOTA and NODAGA. Bioconjug Chem 24: 1102-1109, 2013.
48. Gong H, Kovar J, Little G, Chen H and Olive DM: In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore. Neoplasia 12: 139-149, 2010.
49. Kobayashi H, Kao CH, Kreitman RJ, Le N, Kim MK, Brechbiel MW, Paik CH, Pastan I and Carrasquillo JA: Pharmacokinetics of 111In-and 125I-labeled antiTac single-chain Fv recombinant immunotoxin. J Nucl Med 41: 755-762, 2000.
50. Tolmachev V, Velikyan I, Sandström M and Orlova A: A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: Direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 37: 1356-1367, 2010.
51. Barta P, Malmberg J, Melicharova L, Strandgård J, Orlova A, Tolmachev V, Laznicek M and Andersson K: Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. Int J Oncol 40: 1677-1682, 2012.
52. Kobayashi H, Yoo TM, Kim IS, Kim MK, Le N, Webber KO, Pastan I, Paik CH, Eckelman WC and Carrasquillo JA: L-lysine effectively blocks renal uptake of 125I-or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. Cancer Res 56: 3788-3795, 1996.
53. Altai M, Varasteh Z, Andersson K, Eek A, Boerman O and Orlova A: In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors. Cancer Biother Radiopharm 28: 187-195, 2013.
54. Ahlgren S, Orlova A, Wållberg H, Hansson M, Sandström M, Lewsley R, Wennborg A, Abrahmsén L, Tolmachev V and Feldwisch J: Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med 51: 1131-1138, 2010.